Publications
239
Citations
13,169
Est. group size
~20
Recurring co-author estimate
Active years
24
Publishing since 2003
Amy S. Ruppert works in blood cancer clinical research, focusing on clinical trials for chronic lymphocytic leukemia, lymphoma, and related blood cancers, particularly studies of the drug pirtobrutinib (a BTK inhibitor used to block cancer cell growth signals). Much of this work involves biostatistics and clinical trial design, including analysis of patient-reported outcomes (how patients themselves describe symptoms and quality of life) to evaluate treatment safety and effectiveness.
Publication output grew steadily from 2017 through a peak in 2023, then declined in 2024-2025 before showing signs of picking back up in 2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library
Figshare · 2026
- Additional file 1 of Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library
Figshare · 2026
- Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library
Figshare · 2026
- Additional file 1 of Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library
Figshare · 2026
- Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library
Journal of Patient-Reported Outcomes · 2026
- Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting
Journal of Geriatric Oncology · 2026
- Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial
The Lancet Haematology · 2026
- CO190 Optimal Categorization of High Side-effect Bother Based on Functional Assessment of Cancer Therapy GP5 (FACT-GP5) Item Among Patients with MCL enrolled to BRUIN-MCL-321
Value in Health · 2025
- BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Journal of Clinical Oncology · 2025
- PCR91 Patient Reported Outcomes in BRUIN CLL-321: A Phase 3 Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Value in Health · 2025
- Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101
Blood Advances · 2024
- CT-168 Comparison of Bleeding-Related Events in Patients Who Received Pirtobrutinib With and Without Antithrombotic Agents
Clinical Lymphoma Myeloma & Leukemia · 2023
- P1108: EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: RESULTS FROM THE PHASE 1/2 BRUIN STUDY
HemaSphere · 2023
- BRUIN MCL-321: A phase 3, open-label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor naïve mantle cell lymphoma.
Journal of Clinical Oncology · 2023
- Statistical Considerations and Software for Designing Sequential, Multiple Assignment, Randomized Trials (SMART) with a Survival Final Endpoint
Journal of Biopharmaceutical Statistics · 2023
- Blood×46
- Journal of Clinical Oncology×18
- Blood Advances×5
- Leukemia×4
- Leukemia & lymphoma/Leukemia and lymphoma×4
- John C. Byrd
Medicine · The Ohio State University
- Kyoko Yamaguchi
Medicine · The Ohio State University
- Cecelia Miller
Medicine · The Ohio State University
- Daniel Jones
Medicine · The Ohio State University
- Michael R. Grever
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile